Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent prior to trial participation.
Human Immunodeficiency Virus type 1 (HIV-1) infected males or females ≥18 years of age.
Acceptable laboratory screening values in Trial 1182.12 (RESIST 1) or 1182.48 (RESIST 2), excluding genotype.
Genotypic resistance report from screening visit of study RESIST 1 or RESIST 2 indicating at least three mutations at protease codons 33, 82, 84, and 90.
At least 3 consecutive months experience taking ARVs from each of the classes of Nucleoside reverse transcriptase inhibitors (NRTI), Non-nucleoside reverse transcriptase inhibitor 1 (NNRTI), and Protease Inhibitor (PI) at some point in treatment history, with at least 2 PI-based regimens, one of which must be part of the current regimen, and current PI-based Anti-retroviral (ARV) medication regimen for at least 3 months prior to randomization.
HIV-1 viral load ≥1000 copies/mL at screening.
You may not be if
Anti-retroviral (ARV) medication naïve.
Patients on recent drug holiday, defined as off ARV medications for at least 7 consecutive days within the last 3 months.
Female patients of child-bearing potential who:
* have a positive serum pregnancy test at screening or during the study,
* are breast feeding,
* are planning to become pregnant,
* are not willing to a use barrier method of contraception, or
* require ethinyl estradiol administration.
Prior tipranavir use.
Use of investigational medications within 30 days before study entry or during the trial.
